2 results match your criteria: "China. meiying@hospital.cqmu.edu.cn.[Affiliation]"
Identification of novel KRAS neoantigen specific TCRs and a strategy to eliminate off-target recognition.
J Transl Med
January 2025
Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Background: T cell receptor (TCR)-engineered T cells targeting neoantigens originated from mutations in KRAS gene have demonstrated promising outcomes in clinical trials against solid tumors. However, the challenge lies in developing tumor-specific TCRs that avoid cross-reactivity with self-antigens to minimize the possibility of severe clinical toxicities. Current research efforts have been put towards strategies to eliminate TCR off-target recognition.
View Article and Find Full Text PDFSMAD4 depletion contributes to endocrine resistance by integrating ER and ERBB signaling in HR + HER2- breast cancer.
Cell Death Dis
June 2024
Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, 400016, Chongqing, China.
Article Synopsis
- - Endocrine resistance is a major issue for patients with hormone receptor-positive, HER2-negative breast cancer, often linked to dysregulation of estrogen receptor (ER) and ERBB signaling pathways, though how these pathways interact is not fully understood.
- - The study investigates SMAD4's role in this resistance, finding that lower SMAD4 levels in breast cancer tissues correlate with poor patient outcomes, and that its depletion triggers resistance to endocrine therapy by enhancing ER and ERBB signaling.
- - The results suggest that targeting SMAD4 alongside ER, ERBB, and autophagy pathways could offer a new treatment approach for patients facing endocrine resistance in HR+ HER2- breast cancer.